Multiple Myeloma
Showing NaN - NaN of 110
Multiple Myeloma Trial in Worldwide (Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder)
Active, not recruiting
- Multiple Myeloma
- Belantamab mafodotin frozen liquid
- Belantamab mafodotin lyophilized powder
-
New Haven, Connecticut
- +58 more
Jul 27, 2022
Multiple Myeloma Trial in Worldwide (bb2121)
Active, not recruiting
- Multiple Myeloma
- bb2121
-
San Francisco, California
- +47 more
Jul 18, 2022
NSCLC, Ovarian Cancer, Fallopian Tube Cancer Trial in United States (CART-TnMUC1, Cyclophosphamide, Fludarabine)
Active, not recruiting
- Non-Small Cell Lung Cancer
- +5 more
- CART-TnMUC1
- +2 more
-
Phoenix, Arizona
- +9 more
Jul 18, 2022
Multiple Myeloma Trial in Worldwide (CTX120)
Active, not recruiting
- Multiple Myeloma
- CTX120
-
Chicago, Illinois
- +9 more
Jul 14, 2022
Multiple Myeloma Trial in Canada, United States (PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 +
Active, not recruiting
- Multiple Myeloma
- PF-06863135 monotherapy IV or SC
- +3 more
-
Encinitas, California
- +37 more
Jul 7, 2022
Multiple Myeloma Trial in United States (bb2121, Fludarabine, Cyclophosphamide)
Active, not recruiting
- Multiple Myeloma
- bb2121
- +3 more
-
Scottsdale, Arizona
- +19 more
Jul 7, 2022
Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Pomalidomide, Dexamethasone)
Recruiting
- Multiple Myeloma
- Belantamab mafodotin
- +3 more
-
Tucson, Arizona
- +131 more
Jul 1, 2022
Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma Trial in Nashville (Patient-reported outcome measure,
Recruiting
- Chronic Myeloid Leukemia
- +3 more
- Patient-reported outcome measure
- +2 more
-
Nashville, TennesseeVanderbilt University Medical Center
Jun 1, 2022
Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)
Active, not recruiting
- Multiple Myeloma
- +19 more
- CYNK-001
-
Denver, Colorado
- +8 more
May 24, 2022
Multiple Myeloma Trial in United States (KRdD followed by auto-HCT, KRdD only)
Active, not recruiting
- Multiple Myeloma
- KRdD followed by auto-HCT
- KRdD only
-
Birmingham, Alabama
- +3 more
Mar 26, 2022
Presentation, Treatment Patterns, and Outcomes in Multiple
Completed
- Multiple Myeloma
- No Intervention
-
Little Rock, Arkansas
- +136 more
Feb 15, 2022
Multiple Myeloma Trial in United States (panobinostat, carfilzomib)
Completed
- Multiple Myeloma
-
Denver, Colorado
- +12 more
Jan 4, 2022